AtrimusRx launches personalized 3D-printed pediatric medicines at Swedish pharmacy

Swedish pharmaceutical company AtrimusRx has introduced personalized 3D-printed medicines for pediatric patients at its community pharmacy in Stockholm, becoming the first pharmacy operator in Sweden to deploy additive manufacturing for extemporaneous compounding in outpatient care. The company’s Atrimus Px™ framework uses validated pharmaceutical-grade 3D printing to produce dosage forms tailored to individual patient needs, starting from 2 mg with dose adjustments at quarter-milligram increments. The technology eliminates the need to split or crush adult tablets for children, addressing a longstanding clinical gap where commercially available pediatric formulations are insufficient. AtrimusRx holds both wholesale distribution and community pharmacy licenses and is a partner in the EU4Health-funded RoboPharma project, which aims to develop decentralized pharmaceutical manufacturing solutions integrating 3D-inspired robotic dosing and AI-driven analytics.

This deployment represents a rare instance of additive manufacturing moving beyond prototyping and into regulated, patient-facing pharmaceutical production within a community pharmacy setting. The pediatric dosing problem is well-documented: approximately 50% of medicines used in children have never been studied in pediatric populations, forcing off-label manipulation of adult formulations. AtrimusRx’s approach directly addresses dosing variability and safety risks inherent in tablet splitting and crushing. The company’s validated compounding process, operating under the Atrimus Px™ framework, positions it within the broader trend toward decentralized, point-of-care pharmaceutical manufacturing — a segment that has seen growing policy interest from the EU and US regulators post-pandemic. The technology is not a novel drug delivery platform but a manufacturing workflow adaptation, which lowers the regulatory barrier compared to developing new chemical entities. Competitors in the pharmaceutical 3D printing space include Aprecia Pharmaceuticals (ZipDose platform, FDA-approved for epilepsy) and Triastek (3D-printed oral solid dosage forms in clinical trials), but AtrimusRx differentiates by operating directly within a licensed pharmacy, not a centralized manufacturing facility.

For the additive manufacturing industry, this is a concrete validation that 3D printing can serve a genuine clinical need — dose individualization — where conventional manufacturing cannot economically compete. The practical significance is narrow but real: AtrimusRx must now demonstrate that its compounding workflow can scale across multiple pharmacies without compromising quality assurance or regulatory compliance. The RoboPharma project provides a structured pathway for that expansion, but the company’s immediate challenge is building prescriber trust and integrating its platform into existing pharmacy workflows. For buyers — primarily pediatricians and hospital pharmacists — the value proposition is clear: a validated, traceable alternative to manual tablet manipulation. This is not a mass-market play, but a targeted solution for a specific regulatory and clinical gap.